Our mission is to enable immediate detection of treatment response in support of precision medicine across cancer therapies and emerging immunotherapies.

Lodestone’s biomarker monitoring technology provides signals of efficacy to guide the development of emerging immunotherapies during preclinical development.

Non-invasive, longitudinal, real-time monitoring of signaling factors in the tumor microenvironment will accelerate clinical trials and enable true precision medicine as the new standard of care.